J. Goldman & CO LP Avidity Biosciences, Inc. Transaction History
J. Goldman & CO LP
- $3.35 Billion
- Q3 2025
A detailed history of J. Goldman & CO LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 8,039 shares of RNA stock, worth $569,161. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,039Holding current value
$569,161% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
312Shares Held
139MCall Options Held
1.24MPut Options Held
526K-
Janus Henderson Group PLC London, X014.5MShares$1.03 Billion0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$936 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY11.4MShares$805 Million6.62% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$713 Million0.08% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.79MShares$693 Million0.05% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $3.69B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...